4/A: Fulgent Genetics CEO Amends Ownership Filing

Fulgent Genetics CEO Ming Hsieh amended a Form 4 filing to include The Ming Hsieh Trust and detail the cancellation of a prepaid variable forward agreement involving 750,000 shares.

Summary

• An amendment to a Form 4 originally filed on March 11, 2026, was submitted solely to add The Ming Hsieh Trust as an additional reporting person.
• No new transactions are being reported in this amendment; it clarifies a previously reported event and adds a reporting person.
• The Ming Hsieh Trust, for which Mr. Hsieh serves as trustee, cancelled a prepaid variable forward agreement (the "2023 Agreement") on March 9, 2026.
• The 2023 Agreement, initially entered into on August 21, 2023, obligated the Hsieh Trust to deliver up to 750,000 shares of Fulgent Genetics common stock or an equivalent cash amount.
• In connection with the cancellation, the Hsieh Trust paid an aggregate of $10,708,875 to the unaffiliated bank.
• Following this payment and cancellation, the 750,000 shares previously subject to the forward contract are no longer pledged to the bank.
• Ming Hsieh's beneficial ownership includes 900,634 shares directly, 7,895,115 shares indirectly via The Ming Hsieh Trust, 220,816 shares indirectly via the Dynasty Trust, 1,000 shares via a Uniform Transfer to Minor Account, and 1,000 shares via an immediate family member.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the payment for contract cancellation is a cash outflow for the insider, the unpledging of shares provides greater flexibility. The primary purpose of the amendment is a technical correction, not a reflection of company performance.

Positives

• 750,000 shares of common stock previously subject to a forward sale contract are no longer pledged, providing greater flexibility for The Ming Hsieh Trust.

Negatives

• The Hsieh Trust incurred a payment of $10,708,875 to cancel the forward agreement, representing a significant cash outflow for the trust.

Future Outlook

No forward-looking statements or guidance are provided in this amendment to the Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings, particularly amendments, are standard regulatory disclosures for insider transactions and beneficial ownership changes. The cancellation of a forward sale contract by a significant insider like a CEO can reflect a strategic decision regarding personal liquidity, risk management, or a change in outlook on the underlying stock, though the filing itself does not provide the rationale.

Related Party Transactions

• The filing details a transaction by the CEO's trust, The Ming Hsieh Trust, which is a related party. The cancellation of the prepaid variable forward agreement involved a payment of $10,708,875 to an unaffiliated bank.

Stakeholder Impact

• Shareholders: The unpledging of 750,000 shares by a significant insider could be viewed positively as it removes a potential overhang, though the insider's payment is a personal financial event. The amendment itself is a compliance update.

Key Dates

Recommendation

This Form 4/A filing primarily serves as a technical amendment to correct a previous filing and clarify an insider's derivative transaction. It does not contain information directly related to the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The cancellation of the forward contract by the CEO's trust is a personal financial decision, and while it unpledges a significant block of shares, it also involved a substantial payment, making its overall impact on the company's investment thesis neutral without further context.

Keywords

Fulgent Genetics, FLGT, Ming Hsieh, SEC Form 4/A, beneficial ownership, prepaid variable forward, stock pledge, insider transaction, trust, common stock